Methylthioninium chloride - Provepharm

Drug Profile

Methylthioninium chloride - Provepharm

Alternative Names: Methylene blue injection - Provepharm; Methylthioninium Chloride Hydrate; Methylthioninium chloride solution for injection; Proveblue

Latest Information Update: 22 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Provepharm
  • Developer Daiichi Sankyo Company; Provepharm
  • Class Antimalarials; Antivirals; Phenothiazines; Small molecules
  • Mechanism of Action Monoamine oxidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Haemoglobinopathies
  • Preclinical Malaria; Viral infections

Most Recent Events

  • 09 Apr 2015 The product is approved for Haemoglobinopathies in European Union
  • 20 Mar 2015 Launched for Haemoglobinopathies (In adolescents, In adults, In children, In infants, In neonates) in Japan (IV)
  • 26 Dec 2014 Registered for Haemoglobinopathies (In adolescents, In adults, In children, In infants, In neonates) in Japan (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top